Shots:
The company reported the results from the (MOMENTUM 3) trial evaluating the long-term outcomes of the HeartMate 3 left ventricular assist device in patients with advanced heart failure
The results showed that the heart pump helps to extend the survival to 5yrs. and beyond for HF patients, improvement in a survival rate of 58% with HeartMate 3 Heart Pump over 44% with HeartMate II, reduction in deaths due to stroke, clotting, and bleeding over HeartMate II
The device also provides clear lifesaving options along with a significant survival benefit of Abbott’s heart pump technology without a heart pump or transplant who have limited therapeutic options with a median survival to ≤1yr.
Ref: Abbott | Image: Abbott
